Fw: NATAP/EASL-Pegasys SVR Durable 99% Cure: 5 Year Followup

[Guest guest]

SVR Durable (99%) After 5 Years of Followup Reported by Jules LevinEASL, April 11-15, 2007Barcelona, SpainMark Swain from Canada looked at the durability of Sustained Viral Responses with Pegasys based therapy. He called these patients cured. Swain reported 5 year followup on 997 treatment-naïve patients who achieved an SVR who received Pegasys monotherapy (3 studies) or Pegasys + ribavirin (6 studies) in one of 9 studies. This included 163 patients who received Pegasys monotherapy, 741 who received Pegasys plus ribavirin combination therapy, and 93 HCV/HIV coinfected patients who received Pegasys with or without ribavirin. Achievement of an SVR was defined as undetectable HCV RNA (50 IU/mL) at 24 weeks after completing treatment. Annual testing was performed for 5 years for HCV RNA in serum with the COBAS AMPLICOR HCV test v2.0 (limit of detection 50 IU/mL). Overall 99.2% of patients who achieved an SVR remained HCV RNA undetectable at a mean of 4.1 (0.4-7) years follow-up. Of note, this high rate of durability was the same regardless of whether patients received monotherapy (98.8%), combination therapy (99.2%), combination therapy with normal ALT (100% n=75), or were coinfected (98.9%). He combined the results of whether you received mono- or combination for the coinfected patients. 8 patients (0.8%) who achieved an SVR became HCV RNA-positive a mean 2 (1.1-2.9) years after completing therapy, and Swain said “it is currently unclear whether patients who became HCV RNA detectable during follow-up experienced re-infection, rather than virological relapse. Regrading the 8 patients with detectable HCV RNA, Swain showed characteristics of these patients and “there appear to be no common risk factors associated with detectability of HCV RNA during follow-upâ€. None of the 8 had cirrhosis; 5 had 48 weeks therapy & 3 had 24 weeks therapy. Several received monotherapy with peg, several received 800 mg RBV and several received 1000/1200 mg RBV. Most of the 8 were Caucasian. The Nine StudiesPatients with a durable SVR at mean 4.1 (0.4 to 7) years follow-up8 patients with an SVR but detectable HCV RNA at long-term follow-up8 patients with an SVR but detectable HCV RNA at long-term follow-up: Characteristic

[Guest guest]

Liz, This is the study that I was talking about last week, It looks

thorough to me, in fact 997 subjects is more than most studies I've

seen.

Are you still skeptical about it?

If I'm still undetectable in August I'm going to consider myself

cured.

Lee

>

>

>

>

>

> SVR Durable (99%) After 5 Years of Followup

>

> Reported by Jules Levin

> EASL, April 11-15, 2007

> Barcelona, Spain

>

> Mark Swain from Canada looked at the durability of Sustained Viral

Responses with Pegasys based therapy. He called these patients cured.

Swain reported 5 year followup on 997 treatment-naïve patients who

achieved an SVR who received Pegasys monotherapy (3 studies) or

Pegasys + ribavirin (6 studies) in one of 9 studies. This included

163 patients who received Pegasys monotherapy, 741 who received

Pegasys plus ribavirin combination therapy, and 93 HCV/HIV coinfected

patients who received Pegasys with or without ribavirin. Achievement

of an SVR was defined as undetectable HCV RNA (50 IU/mL) at 24 weeks

after completing treatment. Annual testing was performed for 5 years

for HCV RNA in serum with the COBAS AMPLICOR HCV test v2.0 (limit of

detection 50 IU/mL). Overall 99.2% of patients who achieved an SVR

remained HCV RNA undetectable at a mean of 4.1 (0.4-7) years follow-

up. Of note, this high rate of durability was the same regardless of

whether patients received monotherapy (98.8%), combination therapy

(99.2%), combination therapy with normal ALT (100% n=75), or were

coinfected (98.9%). He combined the results of whether you received

mono- or combination for the coinfected patients. 8 patients (0.8%)

who achieved an SVR became HCV RNA-positive a mean 2 (1.1-2.9) years

after completing therapy, and Swain said â?oit is currently unclear

whether patients who became HCV RNA detectable during follow-up

experienced re-infection, rather than virological relapse. Regrading

the 8 patients with detectable HCV RNA, Swain showed characteristics

of these patients and â?othere appear to be no common risk factors

associated with detectability of HCV RNA during follow-upâ?. None of

the 8 had cirrhosis; 5 had 48 weeks therapy & 3 had 24 weeks therapy.

Several received monotherapy with peg, several received 800 mg RBV

and several received 1000/1200 mg RBV. Most of the 8 were Caucasian.

>

> The Nine Studies

>

>

> Patients with a durable SVR at mean 4.1 (0.4 to 7) years follow-up

>

>

> 8 patients with an SVR but detectable HCV RNA at long-term follow-up

>

>

> 8 patients with an SVR but detectable HCV RNA at long-term follow-

up: Characteristic

>

[Guest guest]

Lee,, IF you decide to consider yourself 'cured',, please do not return to alcohol , IF you ever drank it anyway,, I have no idea, but I DO know a lady who relapsed after 10 years BECAUSE she went on a 4 month bender... THATS NOT worth it,, I dont ever want to have to do tx again, I will if I needed to but I hope now..Lee <leecuate@...> wrote: Liz, This is the study that I was talking about last week, It looks thorough to me, in fact 997 subjects is more than most studies I've seen.Are you still skeptical about

it?If I'm still undetectable in August I'm going to consider myself cured.Lee>> > > > > SVR Durable (99%) After 5 Years of Followup > > Reported by Jules Levin> EASL, April 11-15, 2007> Barcelona, Spain> > Mark Swain from Canada looked at the durability of Sustained Viral Responses with Pegasys based therapy. He called these patients cured. Swain reported 5 year followup on 997 treatment-naïve patients who achieved an SVR who received Pegasys monotherapy (3 studies) or Pegasys + ribavirin (6 studies) in one of 9 studies. This included 163 patients who received Pegasys monotherapy, 741 who received Pegasys plus ribavirin combination therapy, and 93 HCV/HIV coinfected

patients who received Pegasys with or without ribavirin. Achievement of an SVR was defined as undetectable HCV RNA (50 IU/mL) at 24 weeks after completing treatment. Annual testing was performed for 5 years for HCV RNA in serum with the COBAS AMPLICOR HCV test v2.0 (limit of detection 50 IU/mL). Overall 99.2% of patients who achieved an SVR remained HCV RNA undetectable at a mean of 4.1 (0.4-7) years follow-up. Of note, this high rate of durability was the same regardless of whether patients received monotherapy (98.8%), combination therapy (99.2%), combination therapy with normal ALT (100% n=75), or were coinfected (98.9%). He combined the results of whether you received mono- or combination for the coinfected patients. 8 patients (0.8%) who achieved an SVR became HCV RNA-positive a mean 2 (1.1-2.9) years after completing therapy, and Swain said â?oit is currently unclear whether patients who became HCV RNA

detectable during follow-up experienced re-infection, rather than virological relapse. Regrading the 8 patients with detectable HCV RNA, Swain showed characteristics of these patients and â?othere appear to be no common risk factors associated with detectability of HCV RNA during follow-upâ?. None of the 8 had cirrhosis; 5 had 48 weeks therapy & 3 had 24 weeks therapy. Several received monotherapy with peg, several received 800 mg RBV and several received 1000/1200 mg RBV. Most of the 8 were Caucasian. > > The Nine Studies> > > Patients with a durable SVR at mean 4.1 (0.4 to 7) years follow-up> > > 8 patients with an SVR but detectable HCV RNA at long-term follow-up> > > 8 patients with an SVR but detectable HCV RNA at long-term follow-up: Characteristic>Jackie

[Guest guest]

Lee like I said before there is no cure yet .......even those that reach SVR have the virus still it's just not doing damage . But if if makes you feel better to say your cured then say it just dont start slipping back into a lifestyle that will cause the virus to rear it head again .

Re: Fw: NATAP/EASL-Pegasys SVR Durable 99% Cure: 5 Year Followup

Liz, This is the study that I was talking about last week, It looks thorough to me, in fact 997 subjects is more than most studies I've seen.Are you still skeptical about it?If I'm still undetectable in August I'm going to consider myself cured.Lee>> > > > > SVR Durable (99%) After 5 Years of Followup > > Reported by Jules Levin> EASL, April 11-15, 2007> Barcelona, Spain> > Mark Swain from Canada looked at the durability of Sustained Viral Responses with Pegasys based therapy. He called these patients cured. Swain reported 5 year followup on 997 treatment-naïve patients who achieved an SVR who received Pegasys monotherapy (3 studies) or Pegasys + ribavirin (6 studies) in one of 9 studies. This included 163 patients who received Pegasys monotherapy, 741 who received Pegasys plus ribavirin combination therapy, and 93 HCV/HIV coinfected patients who received Pegasys with or without ribavirin. Achievement of an SVR was defined as undetectable HCV RNA (50 IU/mL) at 24 weeks after completing treatment. Annual testing was performed for 5 years for HCV RNA in serum with the COBAS AMPLICOR HCV test v2.0 (limit of detection 50 IU/mL). Overall 99.2% of patients who achieved an SVR remained HCV RNA undetectable at a mean of 4.1 (0.4-7) years follow-up. Of note, this high rate of durability was the same regardless of whether patients received monotherapy (98.8%), combination therapy (99.2%), combination therapy with normal ALT (100% n=75), or were coinfected (98.9%). He combined the results of whether you received mono- or combination for the coinfected patients. 8 patients (0.8%) who achieved an SVR became HCV RNA-positive a mean 2 (1.1-2.9) years after completing therapy, and Swain said â?oit is currently unclear whether patients who became HCV RNA detectable during follow-up experienced re-infection, rather than virological relapse. Regrading the 8 patients with detectable HCV RNA, Swain showed characteristics of these patients and â?othere appear to be no common risk factors associated with detectability of HCV RNA during follow-upâ?. None of the 8 had cirrhosis; 5 had 48 weeks therapy & 3 had 24 weeks therapy. Several received monotherapy with peg, several received 800 mg RBV and several received 1000/1200 mg RBV. Most of the 8 were Caucasian. > > The Nine Studies> > > Patients with a durable SVR at mean 4.1 (0.4 to 7) years follow-up> > > 8 patients with an SVR but detectable HCV RNA at long-term follow-up> > > 8 patients with an SVR but detectable HCV RNA at long-term follow-up: Characteristic>

[Guest guest]

Don't worry Jackie.

I don't miss alcohol, but it would be nice to have a glass of wine

with dinner when I'm at a restaurant.

Lee

> >

> >

> >

> >

> >

> > SVR Durable (99%) After 5 Years of Followup

> >

> > Reported by Jules Levin

> > EASL, April 11-15, 2007

> > Barcelona, Spain

> >

> > Mark Swain from Canada looked at the durability of Sustained

Viral

> Responses with Pegasys based therapy. He called these patients

cured.

> Swain reported 5 year followup on 997 treatment-naïve patients who

> achieved an SVR who received Pegasys monotherapy (3 studies) or

> Pegasys + ribavirin (6 studies) in one of 9 studies. This included

> 163 patients who received Pegasys monotherapy, 741 who received

> Pegasys plus ribavirin combination therapy, and 93 HCV/HIV

coinfected

> patients who received Pegasys with or without ribavirin.

Achievement

> of an SVR was defined as undetectable HCV RNA (50 IU/mL) at 24

weeks

> after completing treatment. Annual testing was performed for 5

years

> for HCV RNA in serum with the COBAS AMPLICOR HCV test v2.0 (limit

of

> detection 50 IU/mL). Overall 99.2% of patients who achieved an SVR

> remained HCV RNA undetectable at a mean of 4.1 (0.4-7) years follow-

> up. Of note, this high rate of durability was the same regardless

of

> whether patients received monotherapy (98.8%), combination therapy

> (99.2%), combination therapy with normal ALT (100% n=75), or were

> coinfected (98.9%). He combined the results of whether you received

> mono- or combination for the coinfected patients. 8 patients (0.8%)

> who achieved an SVR became HCV RNA-positive a mean 2 (1.1-2.9)

years

> after completing therapy, and Swain said â?oit is currently unclear

> whether patients who became HCV RNA detectable during follow-up

> experienced re-infection, rather than virological relapse.

Regrading

> the 8 patients with detectable HCV RNA, Swain showed

characteristics

> of these patients and â?othere appear to be no common risk factors

> associated with detectability of HCV RNA during follow-upâ?. None

of

> the 8 had cirrhosis; 5 had 48 weeks therapy & 3 had 24 weeks

therapy.

> Several received monotherapy with peg, several received 800 mg RBV

> and several received 1000/1200 mg RBV. Most of the 8 were

Caucasian.

> >

> > The Nine Studies

> >

> >

> > Patients with a durable SVR at mean 4.1 (0.4 to 7) years follow-up

> >

> >

> > 8 patients with an SVR but detectable HCV RNA at long-term follow-

up

> >

> >

> > 8 patients with an SVR but detectable HCV RNA at long-term follow-

> up: Characteristic

> >

>

>

>

>

>

>

> Jackie

>

[Guest guest]

Liz,

Didn't that study find a few cases where they didn't find any virus.

I'm also wondering, can't they find traces of every cold, flu and

other viruses that we have been exposed to in our lives if they look

hard enough.

Lee

> >

> >

> >

> >

> >

> > SVR Durable (99%) After 5 Years of Followup

> >

> > Reported by Jules Levin

> > EASL, April 11-15, 2007

> > Barcelona, Spain

> >

> > Mark Swain from Canada looked at the durability of Sustained

Viral

> Responses with Pegasys based therapy. He called these patients

cured.

> Swain reported 5 year followup on 997 treatment-naïve patients

who

> achieved an SVR who received Pegasys monotherapy (3 studies) or

> Pegasys + ribavirin (6 studies) in one of 9 studies. This

included

> 163 patients who received Pegasys monotherapy, 741 who received

> Pegasys plus ribavirin combination therapy, and 93 HCV/HIV

coinfected

> patients who received Pegasys with or without ribavirin.

Achievement

> of an SVR was defined as undetectable HCV RNA (50 IU/mL) at 24

weeks

> after completing treatment. Annual testing was performed for 5

years

> for HCV RNA in serum with the COBAS AMPLICOR HCV test v2.0 (limit

of

> detection 50 IU/mL). Overall 99.2% of patients who achieved an

SVR

> remained HCV RNA undetectable at a mean of 4.1 (0.4-7) years

follow-

> up. Of note, this high rate of durability was the same regardless

of

> whether patients received monotherapy (98.8%), combination

therapy

> (99.2%), combination therapy with normal ALT (100% n=75), or were

> coinfected (98.9%). He combined the results of whether you

received

> mono- or combination for the coinfected patients. 8 patients

(0.8%)

> who achieved an SVR became HCV RNA-positive a mean 2 (1.1-2.9)

years

> after completing therapy, and Swain said â?oit is currently

unclear

> whether patients who became HCV RNA detectable during follow-up

> experienced re-infection, rather than virological relapse.

Regrading

> the 8 patients with detectable HCV RNA, Swain showed

characteristics

> of these patients and â?othere appear to be no common risk

factors

> associated with detectability of HCV RNA during follow-upâ?.

None of

> the 8 had cirrhosis; 5 had 48 weeks therapy & 3 had 24 weeks

therapy.

> Several received monotherapy with peg, several received 800 mg

RBV

> and several received 1000/1200 mg RBV. Most of the 8 were

Caucasian.

> >

> > The Nine Studies

> >

> >

> > Patients with a durable SVR at mean 4.1 (0.4 to 7) years follow-

up

> >

> >

> > 8 patients with an SVR but detectable HCV RNA at long-term

follow-up

> >

> >

> > 8 patients with an SVR but detectable HCV RNA at long-term

follow-

> up: Characteristic

> >

>

[Guest guest]

Try the non-alcohol ones they offer in resturants Lee. Yeah it is grape juice with a sparkle. But really the taste is about the same. We did that for New Year's eve this year and even My Breianna was able to have a glass. We hauled out the champaine flutes and toasted the New Year end.Lee <leecuate@...> wrote: Don't worry Jackie.I don't miss alcohol, but it would

be nice to have a glass of wine with dinner when I'm at a restaurant.Lee> >> > > > > > > > > > SVR Durable (99%) After 5 Years of Followup > > > > Reported by Jules Levin> > EASL, April 11-15, 2007> > Barcelona, Spain> > > > Mark Swain from Canada looked at the durability of Sustained Viral > Responses with Pegasys based therapy. He called these patients cured. > Swain reported 5 year followup on 997 treatment-naïve patients who > achieved an SVR who received Pegasys monotherapy (3 studies) or > Pegasys + ribavirin (6 studies) in one of 9 studies. This included > 163 patients who received Pegasys monotherapy, 741 who received > Pegasys plus ribavirin combination therapy, and 93 HCV/HIV coinfected

> patients who received Pegasys with or without ribavirin. Achievement > of an SVR was defined as undetectable HCV RNA (50 IU/mL) at 24 weeks > after completing treatment. Annual testing was performed for 5 years > for HCV RNA in serum with the COBAS AMPLICOR HCV test v2.0 (limit of > detection 50 IU/mL). Overall 99.2% of patients who achieved an SVR > remained HCV RNA undetectable at a mean of 4.1 (0.4-7) years follow-> up. Of note, this high rate of durability was the same regardless of > whether patients received monotherapy (98.8%), combination therapy > (99.2%), combination therapy with normal ALT (100% n=75), or were > coinfected (98.9%). He combined the results of whether you received > mono- or combination for the coinfected patients. 8 patients (0.8%) > who achieved an SVR became HCV RNA-positive a mean 2 (1.1-2.9) years > after completing therapy,

and Swain said â?oit is currently unclear > whether patients who became HCV RNA detectable during follow-up > experienced re-infection, rather than virological relapse. Regrading > the 8 patients with detectable HCV RNA, Swain showed characteristics > of these patients and â?othere appear to be no common risk factors > associated with detectability of HCV RNA during follow-upâ?. None of > the 8 had cirrhosis; 5 had 48 weeks therapy & 3 had 24 weeks therapy. > Several received monotherapy with peg, several received 800 mg RBV > and several received 1000/1200 mg RBV. Most of the 8 were Caucasian. > > > > The Nine Studies> > > > > > Patients with a durable SVR at mean 4.1 (0.4 to 7) years follow-up> > > > > > 8 patients with an SVR but detectable HCV RNA at long-term follow-up> > > > >

> 8 patients with an SVR but detectable HCV RNA at long-term follow-> up: Characteristic> >> > > > > > > Jackie>Life is short, Break the rules, Forgive quickly, Kiss slowly, Love truly, Laugh uncontrollably, And never regret anything that made you smile.

[Guest guest]

ok,, I'll not worry then,, I have just seen ppl who have relapsed after reaching SVR BECAUSE of choices they made.....Lee <leecuate@...> wrote: Don't worry Jackie.I don't miss alcohol, but it would be nice to have a glass of wine with dinner when I'm at a restaurant.Lee> >> > > > > > > > > > SVR Durable (99%) After 5 Years of Followup > > > >

Reported by Jules Levin> > EASL, April 11-15, 2007> > Barcelona, Spain> > > > Mark Swain from Canada looked at the durability of Sustained Viral > Responses with Pegasys based therapy. He called these patients cured. > Swain reported 5 year followup on 997 treatment-naïve patients who > achieved an SVR who received Pegasys monotherapy (3 studies) or > Pegasys + ribavirin (6 studies) in one of 9 studies. This included > 163 patients who received Pegasys monotherapy, 741 who received > Pegasys plus ribavirin combination therapy, and 93 HCV/HIV coinfected > patients who received Pegasys with or without ribavirin. Achievement > of an SVR was defined as undetectable HCV RNA (50 IU/mL) at 24 weeks > after completing treatment. Annual testing was performed for 5 years > for HCV RNA in serum with the COBAS AMPLICOR HCV test v2.0 (limit of

> detection 50 IU/mL). Overall 99.2% of patients who achieved an SVR > remained HCV RNA undetectable at a mean of 4.1 (0.4-7) years follow-> up. Of note, this high rate of durability was the same regardless of > whether patients received monotherapy (98.8%), combination therapy > (99.2%), combination therapy with normal ALT (100% n=75), or were > coinfected (98.9%). He combined the results of whether you received > mono- or combination for the coinfected patients. 8 patients (0.8%) > who achieved an SVR became HCV RNA-positive a mean 2 (1.1-2.9) years > after completing therapy, and Swain said â?oit is currently unclear > whether patients who became HCV RNA detectable during follow-up > experienced re-infection, rather than virological relapse. Regrading > the 8 patients with detectable HCV RNA, Swain showed characteristics > of these patients and â?othere appear to

be no common risk factors > associated with detectability of HCV RNA during follow-upâ?. None of > the 8 had cirrhosis; 5 had 48 weeks therapy & 3 had 24 weeks therapy. > Several received monotherapy with peg, several received 800 mg RBV > and several received 1000/1200 mg RBV. Most of the 8 were Caucasian. > > > > The Nine Studies> > > > > > Patients with a durable SVR at mean 4.1 (0.4 to 7) years follow-up> > > > > > 8 patients with an SVR but detectable HCV RNA at long-term follow-up> > > > > > 8 patients with an SVR but detectable HCV RNA at long-term follow-> up: Characteristic> >> > > > > > > Jackie>Jackie